Transgenic ungulates capable of human antibody production
AssigneeKyowa Hakko Kirin Co., Ltd.
InventorsJames M. Robl, Philippe Collas, Eddie Sullivan, Poothappillai Kasinathan, Richard A. Goldsby, Yoshimi Kuroiwa, Kazuma Tomizuka, Isao Ishida, Barbara Osborne
Life of this patent
Estimating the term…
Abstract
The invention features novel methods for the production of large quantities of xenogenous antibodies, such as human antibodies. Preferably, this result is effected by inactivation of IgM heavy chain expression and, optionally, by inactivation of Ig light chain expression, and by the further introduction of an artificial chromosome which results in the expression of xenogenous antibodies (e.g., non-bovine antibodies), preferably human antibodies.
Claims20
A transgenic ungulate whose genome comprises a mutation in an endogenous immunoglobulin (Ig) heavy chain or Ig light chain locus, said mutation reducing the expression of said Ig heavy chain or Ig light chain.
An isolated ungulate somatic cell comprising a mutation in an endogenous immunoglobulin (Ig) heavy chain or Ig light chain locus, said mutation reducing the expression of said Ig heavy chain or Ig light chain.
Dependencies are inferred from the claim text.